Mostrar el registro sencillo del ítem

dc.contributor.authorAlonso Pérez, Elisa
dc.contributor.authorSuarez Gestal, Marian
dc.contributor.authorCalaza Cabanas, Manuel
dc.contributor.authorKwan, Tony
dc.contributor.authorMajewski, Jacek
dc.contributor.authorGómez-Reino Carnota, Juan Jesús 
dc.contributor.authorGonzález Martínez-Pedrayo, Antonio 
dc.date.accessioned2017-06-07T07:21:18Z
dc.date.available2017-06-07T07:21:18Z
dc.date.issued2011
dc.identifier.citationAlonso-Perez E, Suarez-Gestal M, Calaza M, Kwan T, Majewski J, Gomez-Reino JJ, Gonzalez A. Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. Arthritis Res Ther. 2011 May 31;13(3):R80. doi: 10.1186/ar3343. PMID: 21627826; PMCID: PMC3218890.
dc.identifier.issn1478-6354
dc.identifier.urihttp://hdl.handle.net/20.500.11940/5478
dc.description.abstractINTRODUCTION: Interferon regulatory factor 5 gene (IRF5) polymorphisms are strongly associated with several diseases, including systemic lupus erythematosus (SLE). The association includes risk and protective components. They could be due to combinations of functional polymorphisms and related to cis-regulation of IRF5 expression, but their mechanisms are still uncertain. We hypothesised that thorough testing of the relationships between IRF5 polymorphisms, expression data from multiple experiments and SLE-associated haplotypes might provide useful new information. METHODS: Expression data from four published microarray hybridisation experiments with lymphoblastoid cell lines (57 to 181 cell lines) were retrieved. Genotypes of 109 IRF5 polymorphisms, including four known functional polymorphisms, were considered. The best linear regression models accounting for the IRF5 expression data were selected by using a forward entry procedure. SLE-associated IRF5 haplotypes were correlated with the expression data and with the best cis-regulatory models. RESULTS: A large fraction of variability in IRF5 expression was accounted for by linear regression models with IRF5 polymorphisms, but at a different level in each expression data set. Also, the best models from each expression data set were different, although there was overlap between them. The SNP introducing an early polyadenylation signal, rs10954213, was included in the best models for two of the expression data sets and in good models for the other two data sets. The SLE risk haplotype was associated with high IRF5 expression in the four expression data sets. However, there was also a trend towards high IRF5 expression with some protective and neutral haplotypes, and the protective haplotypes were not associated with IRF5 expression. As a consequence, correlation between the cis-regulatory best models and SLE-associated haplotypes, regarding either the risk or protective component, was poor. CONCLUSIONS: Our analysis indicates that although the SLE risk haplotype of IRF5 is associated with high expression of the gene, cis-regulation of IRF5 expression is not enough to fully account for IRF5 association with SLE susceptibility, which indicates the need to identify additional functional changes in this gene.
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleCis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines
dc.typeArtigoes
dc.authorsophosAlonso-Perez, Elisa
dc.authorsophosSuarez-Gestal, Marian
dc.authorsophosCalaza, Manuel
dc.authorsophosKwan, Tony
dc.authorsophosMajewski, Jacek
dc.authorsophosGomez-Reino, Juan J
dc.authorsophosGonzalez, Antonio
dc.identifier.doi10.1186/ar3343
dc.identifier.isi297149700011
dc.identifier.pmid21627826
dc.identifier.sophos9839
dc.issue.number3
dc.journal.titleARTHRITIS RESEARCH & THERAPY
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Reumatoloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initialR80
dc.page.finalR80
dc.rights.accessRightsopenAccess
dc.rights.accessRightsopenAccess
dc.typesophosArtículo Original
dc.volume.number13


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional